Mean-difference plots by country: Countries with decreased variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching. by Michael Anthony Ruiz (726055)

“…[NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”

Characterization of the optimized nanoparticles (These values are means of a minimum of 5 batches). by Anjuman Arora (750291)

Subjects:

Translocation of EHEC-Hly to mitochondria results in cytosolic cytochrome c release and ΔΨ_m decrease. by Martina Bielaszewska (79970)

“…No cytochrome c was detected at any time in cytosol of control cells (control cyto). …”

Mean-difference plots by country: Countries with decreased variance and no change in mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with decreased variance and increased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with increased variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with no change in variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Rapamycin treatment significantly decreases induction of lytic KSHV proteins. by Lisa A. Nichols (357612)

Inhibition of MRP1 significantly decreases basal and apoptotic GSH efflux. by Parameswaran G. Sreekumar (176748)

“…A decrease in GSH release only in control cells with no additional change in MRP1 inhibited cells was found and H₂O₂ treatment did not cause any further change (D). …”

Mean change in incidence and diagnoses if testing rates decrease. by Richard T. Gray (282417)

MeHg Exposure Makes O-2A/OPCs More Oxidized, Suppresses BrdU Incorporation, and Decreases Cell Division in Clonal Assays by Zaibo Li (273729)

“…Data are presented, for all clones analyzed, in three dimensions such that the <i>x</i>-axis equals the number of progenitors per clone, the <i>z</i>-axis equals the number of oligodendrocytes (Oligo) per clone, and the <i>y</i>-axis equals the number of clones with any given composition. In cultures exposed to MeHg, there was a decrease in the representation of large clones and a proportionate increase in the number of small clones and clones containing oligodendrocytes. …”

The ratio of standard deviation to mean dose (SD/mean) decreases with neuronal dose. by Murat Alp (781371)

HDM exposure results in increased MIP-2 and decreased IFNα and IL-13. by Jennifer A. Phan (535730)

“…HDM exposure increased bronchoalveolar lavage MIP-2 (A), and decreased IFNα (B) and IL13 (C). There was no effect of HDM exposure on BAL protein (D), nor were there any effects of HRV-1B infection alone, or combined effects of HDM exposure and HRV-1B infection on any of these parameters. * indicates a significant difference between groups. …”

Rapamycin decreases Schwann cell markers, whereas statin induces Schwann cell markers. by Andrea Preitschopf (629851)

Single wavelength dose response kinetics for MS2. 254 = LP 254 nm and 285 = UV LED 285 nm. by Daniel Ma (12698752)

Subjects:

Mean daily consultation counts. by Yael Rachamin (6161423)

<i>In-vitro</i> drug release profiles of (a) amlodipine, (b) hydrochlorothiazide, and (c) candesartan. by Anjuman Arora (750291)

Subjects:

FT-IR spectra of (a) amlodipine (b) hydrochlorohiazide and (c) candesartan nanoparticles. by Anjuman Arora (750291)

Subjects:

PK profiles of the developed nanoparticles vs. free drugs in rats (a) amlodipine, (b) hydrochlorothiazide, and (c) candesartan. by Anjuman Arora (750291)

Subjects: